MONMOUTH JUNCTION, New Jersey, June 1, 2016 /PRNewswire/ -- CytoSorbents Corporation , a critical care immunotherapy leader commercializing its flagship CytoSorb(®) blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that Fresenius Medical Care (FMC), its strategic partner for acute care indications in France, Poland, Sweden, Denmark, Finland, and Norway, has officially initiated its CytoSorb(®) sales efforts.
Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO [http://photos.prnewswire.com/prnh/20140408/MM00899LOGO]
As part of its acute care business, Fresenius Medical Care has deployed a commercial team of sales, marketing, and medical experts to drive sales of CytoSorb(®). This team, which is highly experienced and actively sells Fresenius' products into intensive care units, has been trained and is leading CytoSorb(®) marketing and sales efforts throughout the territory. These in-country efforts include, for example, working with nationally recognized key opinion leaders, marketing CytoSorb(®) at intensive care conferences and symposiums, and promoting CytoSorb(®) to customers in the field.
"Our objective is to provide seamless integration of CytoSorb(®) with our dialysis platform to ensure that customers have a consistently positive experience," commented Mr. Christian Schlaeper, Vice President of International Marketing for Fresenius Medical Care. "We believe CytoSorb(®) has the opportunity to significantly improve the treatment of critically-ill patients. We've already spoken with many customers about CytoSorb(®) and the feedback has been extremely positive. While our selling activities have just started, we've already received CytoSorb(®) orders from several accounts."
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "Our collaboration with FMC has been excellent to date. We have been particularly impressed by the effort of their people and attention to detail that they have brought to the partnership. With their large installed base of dialysis machines, ability to rapidly access Intensive Care Units physicians, and the high quality of their marketing and sales organization, we believe FMC has set the stage for a strong CytoSorb(®) market launch and potential future expansion."
About CytoSorbents Corporation (CTSO)
CytoSorb(®) is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb(®) is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb(®) has been used safely in more than 12,000 human treatments to date.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend(TM), ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's websites: http://www.cytosorbents.com [http://www.cytosorbents.com/] and http://www.cytosorb.com [http://www.cytosorb.com/]
About Fresenius Medical Care
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which about 2.8 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,432 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 294,043 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination.
For more information about Fresenius Medical Care, visit the company's website at www.freseniusmedicalcare.com [http://www.freseniusmedicalcare.com/]
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Cytosorbents Contact:Amy VogelInvestor Relations(732) 329-8885 ext. *firstname.lastname@example.org [mailto:email@example.com]
Investor Contact:Lee Roth The Ruth Group646firstname.lastname@example.org [mailto:email@example.com]
Public Relations Contact:Christopher Hippolyte The Ruth Group646firstname.lastname@example.org [mailto:email@example.com]
Web site: http://www.cytosorbents.com/